Literature DB >> 21387368

What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us.

Nina F Schor1.   

Abstract

The aborted trial of semagacestat has led some to invoke unanticipated effects of γ-secretase inhibition on formation of amyloid β. However, the many substrates for γ-secretases and the varied biological effects of each of the resultant cleavage products make ascribing causality much more complex than that.
Copyright © 2011 American Neurological Association.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21387368     DOI： 10.1002/ana.22365

Source DB:  PubMed          Journal:  Ann Neurol        ISSN： 0364-5134            Impact factor:   10.422


  44 in total

1.  Microarray analysis of CA1 pyramidal neurons in a mouse model of tauopathy reveals progressive synaptic dysfunction.

Authors:  Melissa J Alldred; Karen E Duff; Stephen D Ginsberg
Journal:  Neurobiol Dis       Date:  2011-11-07       Impact factor: 5.996

Review 2.  Neurotoxicity of biologically targeted agents in pediatric cancer trials.

Authors:  Elizabeth M Wells; Amulya A Nageswara Rao; Joseph Scafidi; Roger J Packer
Journal:  Pediatr Neurol       Date:  2012-04       Impact factor: 3.372

3.  Why our patients (and we) need basic science research.

Authors:  Nina F Schor
Journal:  Neurology       Date:  2013-05-28       Impact factor: 9.910

Review 4.  Alzheimer mechanisms and therapeutic strategies.

Authors:  Yadong Huang; Lennart Mucke
Journal:  Cell       Date:  2012-03-16       Impact factor: 41.582

Review 5.  Gelsolin amyloidosis: genetics, biochemistry, pathology and possible strategies for therapeutic intervention.

Authors:  James P Solomon; Lesley J Page; William E Balch; Jeffery W Kelly
Journal:  Crit Rev Biochem Mol Biol       Date:  2012-02-24       Impact factor: 8.250

6.  Reducing available soluble β-amyloid prevents progression of cerebral amyloid angiopathy in transgenic mice.

Authors:  Julia L Gregory; Claudia M Prada; Sara J Fine; Monica Garcia-Alloza; Rebecca A Betensky; Michal Arbel-Ornath; Steven M Greenberg; Brian J Bacskai; Matthew P Frosch
Journal:  J Neuropathol Exp Neurol       Date:  2012-11       Impact factor: 3.685

Review 7.  Purinergic receptors as potential therapeutic targets in Alzheimer's disease.

Authors:  Lucas T Woods; Deepa Ajit; Jean M Camden; Laurie Erb; Gary A Weisman
Journal:  Neuropharmacology       Date:  2015-10-28       Impact factor: 5.250

8.  Attenuation of amyloid-β generation by atypical protein kinase C-mediated phosphorylation of engulfment adaptor PTB domain containing 1 threonine 35.

Authors:  Dennis Dik-Long Chau; Kristen Wing-Yu Yung; William Wai-Lun Chan; Ying An; Yan Hao; Ho-Yin Edwin Chan; Jacky Chi-Ki Ngo; Kwok-Fai Lau
Journal:  FASEB J       Date:  2019-08-05       Impact factor: 5.191

9.  γ-Secretase inhibition promotes fibrotic effects of albumin in proximal tubular epithelial cells.

Authors:  C Slattery; Y Jang; W A Kruger; D H Hryciw; A Lee; P Poronnik
Journal:  Br J Pharmacol       Date:  2013-07       Impact factor: 8.739

10.  The role of γ-secretase activating protein (GSAP) and imatinib in the regulation of γ-secretase activity and amyloid-β generation.

Authors:  Ishrut Hussain; Julien Fabrègue; Laurence Anderes; Solenne Ousson; Frédéric Borlat; Valérie Eligert; Sébastien Berger; Mitko Dimitrov; Jean-René Alattia; Patrick C Fraering; Dirk Beher
Journal:  J Biol Chem       Date:  2012-12-03       Impact factor: 5.157
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.